Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05292586 · ClinicalTrials.gov registry record · Phase 3

A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid

A Phase 3 study of Asthma, sponsored by Chiesi Farmaceutici S.p.A..

Completed
Registry status
Phase 3
Development phase
1,377
Enrollment target
20
Study locations

NCT05292586 is a Phase 3 study of Asthma that has completed, run by Chiesi Farmaceutici S.p.A.. The registered enrollment target is 1,377 participants, below the 1,560-participant average among 374 other Asthma trials with a reported enrollment target (12% lower). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05292586, a Phase 3 study of Asthma, has completed, sponsored by Chiesi Farmaceutici S.p.A..

COMPLETED
Registry status
Phase 3
Development phase
1,377 participants
Enrollment target
20
Study locations

Study Summary

Compare the superiority of CHF 1535 versus CHF 718 in subjects with asthma who are on medium or high dose inhaled corticosteroids.

Conditions Studied

Interventions

  • DRUG Beclomethasone Dipropionate/Formoterol Fumarate
  • DRUG Beclomethasone Dipropionate

Study Locations (20)

California

  • Chiesi Clinical Trial Site 840856 - Encinitas
  • Chiesi Clinical Trial Site 840843 - Huntington Beach
  • Chiesi Clinical Trial Site 840860 - Huntington Beach
  • Chiesi Clinical Trial Site 840896 - Long Beach
  • Chiesi Clinical Trial Site 840883 - Los Angeles
  • Chiesi Clinical Trial Site 840810 - Los Angeles
  • Chiesi Clinical Trial Site 840869 - Newport Beach
  • Chiesi Clinical Trial Site 840890 - North Hollywood
  • Chiesi Clinical Trial Site 840808 - Northridge
  • Chiesi Clinical Trial Site 840879 - Pomona
  • Chiesi Clinical Trial Site 840868 - Sacramento
  • Chiesi Clinical Trial Site 840849 - San Diego
  • Chiesi Clinical Trial Site 840877 - San Diego
  • Chiesi Clinical Trial Site 840861 - San Jose
  • Chiesi Clinical Trial Site 840881 - Westminster

Colorado

  • Chiesi Clinical Trial Site 840873 - Colorado Springs
  • Chiesi Clinical Trial Site 840800 - Denver

Alabama

  • Chiesi Clinical Trial Site 840858 - Mobile

Arizona

  • Chiesi Clinical Trial Site 840895 - Chandler

Florida

  • Chiesi Clinical Trial Site 840820 - Coral Gables

Trial Details

FieldValue
Enrollment Target 1,377 participants
Start Date 2022-08-31
Est. Completion 2024-06-24
Phase Phase 3

Sponsor

Chiesi Farmaceutici S.p.A.

30 total trials

What the Registry Record Tells You About NCT05292586

The ClinicalTrials.gov registry entry for NCT05292586 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,377 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,560-participant average among 374 other Asthma trials with a reported enrollment target (12% lower). The listed sponsor is Chiesi Farmaceutici S.p.A., which has 30 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Beclomethasone Dipropionate/Formoterol Fumarate is the first listed.

NCT05292586 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Colorado, Alabama.

Frequently Asked Questions

What is clinical trial NCT05292586 about?

NCT05292586 is a clinical study titled "A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid". Compare the superiority of CHF 1535 versus CHF 718 in subjects with asthma who are on medium or high dose inhaled corticosteroids.

What is the current status of trial NCT05292586?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,377 participants. The study started on 2022-08-31. Estimated completion is 2024-06-24.

What conditions does trial NCT05292586 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT05292586?

The interventions under investigation include: Beclomethasone Dipropionate/Formoterol Fumarate (DRUG), Beclomethasone Dipropionate (DRUG).

Who is sponsoring clinical trial NCT05292586?

This trial is sponsored by Chiesi Farmaceutici S.p.A., which has 30 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05292586 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.